The Novacyt (NCYT) share price: is it set to soar again?

The Novacyt share price (LON: NCYT) collapsed earlier in 2021. But the latest news has sent it heading upwards again. Time to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Novacyt (LSE: NCYT) was a bit of a stock market darling throughout 2020 and into 2021. A couple of super high peaks did quickly decline, but things were still looking pretty rosy.

But then in April, the NCYT share price suddenly nosedived. And since then it’s continued to drift downwards.

Until Wednesday, that is, when we saw the shares climb 20% in just one day. Before I get too excited about that though, I need to put it into perspective. This latest increase puts Novacyt up 24% over the past 12 months. But at its earlier peaks, in October 2020 and again in January 2021, we were looking at gains of 300%.

Novacyt is a specialist in Covid-19 testing. We had been hoping for, and expecting, an effective vaccine since the very start of the pandemic. But it’s been clear for some time the virus will be with us for the long term, just like influenza. And testing demand will presumably continue with it.

The new Novacyt share price spike is down to a first-half update. Total revenue increased by 50% compared to the first half of 2020. Revenue from the firm’s contract with the UK’s Department of Health and Social Care (DHSC), which accounts for 43% of the total, jumped 121%.

Reasons for caution

That’s good, but I’m cautious over the comparatives with last year. They include a period when Novacyt was just getting started with its testing development, before sales had kicked off. My Motley Fool colleague Roland Head has raised a few concerns too, all of which I share. The most important issue, I think, is the reason for April’s price slump.

Novacyt had a contract with the DHSC for the provision of test kits, and expected it to be extended. It didn’t happen, and the announcement of the failure triggered the NCYT share price crash. In addition, there’s an ongoing legal dispute, and I fear that might prove expensive.

Further, it seems £40.8m of 2021 DHSC revenue is actually unpaid and still under dispute. That’s 43% of the first-half total. On the upside, the company still reckons it should achieve around £100m in non-DHSC revenue for the full year. But I really think I’d want to see how the dispute turns out before I’d consider buying.

NCYT share price valuation

On the upside, I can see demand for Covid testing continuing at high levels for the foreseeable future. And based solely on the mooted £100m revenue, Roland estimates a forward P/E multiple of only around seven. That, for a stock with growth potential, looks very attractive. And it does tempt me.

But I don’t know what the balance sheet looks like at the moment, and there are just too many uncertainties for me to invest right now. I generally tend to keep away from companies in legal disputes with their biggest customers too.

I’ll keep watching though, and hoping for future Novacyt share price dips.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Pink 3D image of the numbers '2025' growing in size
Investing Articles

An investor who put £10,000 into Shell shares at the start of the year would now have…

Harvey Jones looks at recent performance of Shell shares, and the factors that could drive the FTSE 100 stock higher…

Read more »

Investing Articles

Growth, dividends, and value! 3 top ETFs to consider for a balanced UK shares portfolio

These London-listed exchange-traded funds (ETFs) could help investors in UK shares enjoy a strong and stable return over time.

Read more »

A row of satellite radars
Investing Articles

If an investor put £10k in Rolls-Royce shares 1 week ago here’s what they’d have now

Rolls-Royce shares started this week where they left off last week Friday, by racing ahead. How much more momentum can…

Read more »

Investing Articles

An investor who put £20,000 into Barclays shares at the start of this year would already have…

Barclays shares have had a brilliant run over the last year and Harvey Jones thinks they're still worth considering as…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here’s why Tesla stock nosedived 27% in February

Hot on the heels of a flat January, Tesla stock had a truly terrible February. What on earth's going on…

Read more »

Investing Articles

£20,000 in a cash ISA? Here’s how an investor could aim to turn that into a £14,900 second income

Can someone turn £20,000 in savings into a £14,900 second income? With enough time, Stephen Wright thinks this could be…

Read more »

Investing Articles

A last-minute growth ETF to consider before next month’s ISA deadline!

With a 540%-plus price rise over nearly a decade, this ETF could be a great investment for ISA investors to…

Read more »

Investing Articles

Here’s why the BAE Systems share price just exploded 17% to an all-time high!

This writer looks at why the BAE Systems share price is up 30% so far in 2025 and asks whether…

Read more »